Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia
Study Details
Study Description
Brief Summary
The primary purpose of this study is to effect of Ingaron®, a lyophilisate for the preparation of a solution for intramuscular and subcutaneous administration of 100,000 IU (LLC NPP Farmaklon, Russia) on the effectiveness of antibiotic therapy in patients with community-acquired pneumonia who fell ill during the epidemiological rise of ARVI.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
N/A |
Detailed Description
Pilot, open, single-centre, randomized controlled trial. Patients will be prescribed basic combination antibiotic therapy. In addition to antibiotic therapy, half of the patients will receive Ingaron®, a lyophilisate for the preparation of a solution for intramuscular and subcutaneous administration of 100,000 IU (LLC NPP Farmaklon, Russia). The study drug solution Ingaron® will be administered intramuscularly at 100,000 IU once daily for 5 days.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Drug: Interferon Gamma Antibacterial therapy + IFN-G administered intramuscularly 100,000 IU once a day daily for 5 days |
Drug: Interferon-Gamma
received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein
Other Names:
|
No Intervention: Control: No intervention Only antibacterial therapy |
Outcome Measures
Primary Outcome Measures
- Time to clinical stabilization of the patient's condition [Day 33]
Assessed by the following parameters: HR < 100 bpm, RR < 24 resp./min, systolic blood pressure ≥90 mmHg, blood saturation level ≥ 90%
Secondary Outcome Measures
- Change in the level of procalcitonin in the blood [Day 10]
Change in the level of procalcitonin in the blood at visit 4 relative to visit 0
- Change in the level of C-reactive protein in the blood [Day 10]
Change in the level of C-reactive protein in the blood at visit 4 relative to visit 0
- Change in blood oxygen saturation [Day 3]
Change in blood oxygen saturation at visit 2 relative to visit 0
- Change in blood oxygen saturation [Day 6]
Change in blood oxygen saturation at visit 3 relative to visit 0
- Change in blood oxygen saturation [Day 10]
Change in blood oxygen saturation at visit 4 relative to visit 0
- Borg Scale changes [Day 10]
Changes on the Borg Scale at visit 4 relative to visit 0, where the minimum score is 0 - dyspnea does not bother, the maximum score is 10 - dyspnea is very pronounced
- Borg Scale changes [Day 31]
Changes on the Borg Scale during a phone call relative to visit 0, where the minimum score is 0 - shortness of breath does not bother, the maximum score is 10 - shortness of breath is very pronounced
- Change in the volume of infiltrates in the lungs according to X-ray data [Day 10]
Change in the volume of infiltrates in the lungs according to X-ray data at visit 4 relative to visit 0
- Difference between body temperature values [Day 3]
Difference between body temperature values Difference between body temperature values (in case of symptom presence according to screening data) at visit 2 relative to visit 0
- Difference between body temperature values [Day 6]
Difference between body temperature values (in case of symptom presence according to screening data) at visit 3 relative to visit 0
- Difference between body temperature values [Day 10]
Difference between body temperature values (in case of symptom presence according to screening data) at visit 4 relative to visit 0
- Change in the level of leukocytes in the blood [Day 3]
Change in the level of leukocytes in the blood at visit 2 relative to visit 0
- Change in the level of leukocytes in the blood [Day 10]
Change in the level of leukocytes in the blood at visit 4 relative to visit 0
- ESR change [Day 10]
ESR change at visit 4 relative to visit 0
- Change in bacterial count in sputum culture [Day 10]
Change in bacterial count in sputum culture at visit 4 relative to visit 0
- Proportion of patients with antibiotic therapy failure [Day 3]
Proportion of patients with antibiotic therapy failure, assessed by the need to change the therapy regimen (add drugs, replace them, or switch to a different dosing regimen or route of administration), lack of signs of clinical stabilization of the condition, or worsening of the course of pneumonia
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients of the inpatient department of both sexes aged 18 to 60 years.
-
Confirmed diagnosis - community-acquired pneumonia (causative agent not specified) of an uncomplicated typical course without respiratory failure and the duration of symptoms is not more than 14 days.
-
Risk class of lethal outcome I-II according to the Fine scale.
-
Availability of an Informed Consent voluntarily signed by the patient.
Exclusion Criteria:
-
Increased individual sensitivity to gamma interferon, Ingaron® and / or excipients that are part of Ingaron® or drugs used in antibacterial therapy.
-
The use of immunomodulating, immunostimulating or immunosuppressive therapy later than 1 month before enrollment in the study.
-
Bronchial asthma and/or COPD.
-
Congestive heart failure.
-
Acute diseases of the gastrointestinal tract or other pathologies that may affect the absorption, distribution, metabolism or excretion of drugs.
-
Chronic liver and / or kidney disease or other pathologies that may affect the absorption, distribution, metabolism or excretion of drugs.
-
Oncological diseases, autoimmune, immunosuppressive conditions at present or according to history.
-
Cerebrovascular pathologies.
-
Diabetes.
-
Pregnancy or lactation.
-
Smoking index over 10 pack/years.
-
Data on severe nervous or mental diseases, including history.
-
Violation of consciousness.
-
Participation of the patient in other studies with the use of drugs or other methods of therapy, including clinical, currently or later than 1 month before inclusion in the study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department | Moscow | Russian Federation | 121374 |
Sponsors and Collaborators
- SPP Pharmaclon Ltd.
Investigators
- Study Director: Anatoly I Saulin, Master, SPP Pharmaclon Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IN/100000-317